Related Experiment Video
Updated: Dec 26, 2025
10:27
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.7K
Targeting DNA-PK in cancer.
1Laboratory of Molecular Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156 Milan, Italy.
Mutation Research
|March 16, 2020
Summary
DNA-dependent protein kinase (DNA-PK) is crucial for DNA repair and genomic stability. Inhibiting DNA-PK offers a promising therapeutic strategy for cancer, particularly when combined with DNA-damaging agents.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- DNA-dependent protein kinase (DNA-PK) plays a vital role in cellular DNA damage response and repair.
- It is essential for maintaining genomic integrity and involved in transcription, immune system development, and telomere protection.
- Dysregulated DNA-PK expression is observed in various cancers, highlighting its significance in tumor biology.
Purpose of the Study:
- To review the multifaceted roles of DNA-PK in cellular processes.
- To explore the involvement of DNA-PK in tumor biology and DNA repair mechanisms.
- To critically evaluate the therapeutic potential of DNA-PK inhibition in cancer treatment.
Main Methods:
- Literature review of existing research on DNA-PK.
- Analysis of DNA-PK's function in DNA double-strand break (DNA-DSB) repair.
- Discussion of small molecule inhibitors and clinical trial data.
Main Results:
- DNA-PK is a key regulator of DNA-DSB repair pathways.
- Its inhibition can sensitize cancer cells to DNA-damaging therapies.
- Several small molecule DNA-PK inhibitors are under clinical investigation.
Conclusions:
- DNA-PK is a significant therapeutic target in oncology.
- Targeting DNA-PK, especially in combination therapies, shows promise for cancer treatment.
- Further research into DNA-PK inhibition is warranted to optimize its clinical application.
Related Concept Videos
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:50Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
02:15M-Cdk Drives Transition Into Mitosis
6.2K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.2K
02:36DNA Damage can Stall the Cell Cycle
9.9K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.9K
02:36DNA Damage Can Stall the Cell Cycle
3.0K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
3.0K
02:23Abnormal Proliferation
5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K